Although numerous technical advances in allogeneic hematopoietic SCT (allo-HSCT) have resulted in a marked decrease in TRM, cardiovascular dysfunction is still one of the most significant complications in allo-HSCT. In about half of the patients with heart failure, cardiac systolic function is preserved, and their symptoms are caused by diastolic dysfunction. Furthermore, even asymptomatic diastolic dysfunction has been reported to affect survival.
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The ratio of early diastolic mitral inflow velocity to early diastolic mitral annulus velocity (E/e′) reflects left ventricular end-diastolic pressure 2 and is used for diagnosis of diastolic heart failure. 3 Although diastolic dysfunction has a crucial role in the development of heart failure, its clinical impact on allo-HSCT is poorly understood. Thus, we retrospectively analyzed diastolic dysfunction using the E/e′ value in 102 evaluable patients who received their first allo-HSCT between November 2010 and July 2012, and investigated whether pretransplant diastolic dysfunction affected clinical outcomes such as cardiac event, OS or non-relapse mortality (NRM) after allo-HSCT. Patient characteristics are summarized in Table 1 . This study analyzed 58 males and 44 females with a median age of 47 years (range: 15-71 years). Patients were classified into an E/e′-high group when the E/e′ value was ⩾ 9 or an E/e′-low group when the E/e′ was o 9; 41 patients were classified into the E/e′-high group and 61 into the E/e′-low group. The median follow-up period was 366 days after HSCT (range: 2-901 days). Compared with the E/e ′-low group, the reduced-intensity conditioning (RIC) regimen was more frequent and the patients were older in the E/e′-high group ( Table 1 ). The cumulative incidence of acute GVHD did not differ significantly between the two groups (P = 0.815). Serum ferritin was measured in 70 patients before their HSCT (38 in E/e′-low and 32 in E/e′-high group) and there was no significant difference (P = 0.396).
A total of 12 patients developed cardiac complications (grade 2 ⩽ in Common Terminology Criteria for Adverse Events ver.4.0) during the first 100 days after allo-HSCT (day 100). Of these, six patients developed heart failure, five developed arrhythmia, and one developed both myocardial ischemia and heart failure simultaneously. Echocardiogram was performed at the onset of cardiac complications in nine patients and three patients showed ejection fraction (EF) ⩽ 50%. The cumulative incidence of cardiac complications at day 100 in the E/e′-high group was significantly higher than that in the E/e′-low group (Figure 1a) . With univariate analysis using Gray's method, older age (447 years), RIC regimen, the cumulative dose of anthracyclines, prolonged corrected QT (QTc) and high E/e′ were significantly related to the development of cardiac complications. The use of TBI (48 Gy) in conditioning regimen did not affect the outcome. During the early phase of HSCT, strain on the heart is increased by various factors such as cytokinemia and rehydration/transfusions. In addition, exercise tolerance decreases in patients with diastolic dysfunction 4 and exercise and/or tachycardia put a load on the poorly compliant left ventricle, eventually leading to reduced stroke volume. 5 Thus, patients with diastolic dysfunction may develop cardiac complications more readily during the early phase of HSCT. In fact, half of the patients with cardiac complications developed infections simultaneously. Although EF o 50% was also statistically significant, we did not consider that EF was related to the development of cardiac complications because only one patient showed EF o50%.
With regard to NRM and OS, patients in the E/e′-high group showed higher NRM and worse OS compared with those in the E/e ′-low group (Figures 1b and c) . Conversely, the relapse rate did not significantly differ between the two groups (P = 0.44).
With multivariate analysis using Fine-Gray proportional hazards model, high-risk disease (hazard ratio (HR): 3.08, 95% confidence interval (CI): 1.17-8.12) and high E/e′ (HR: 2.85, 95% CI: 1.06-7.64) were identified as independent risk factors that significantly affected NRM (other co-variates included HLA compatibility and hematopoietic stem cell transplant-specific comorbidity index). With multivariate analysis using the Cox proportional hazards model, high-risk disease (HR: 5.37, 95% CI: 2.48-11.7), donor source and high E/e′ (HR: 2.27, 95% CI: 1.07-4.82) were identified as risk factors that significantly affected OS (other co-variates included preparative regimen, HLA compatibility, and QTc). Nonrelapse death occurred in 17 patients within 1 year after allo-HSCT. Nine patients died of infection, three died of hemorrhage, two died of GVHD, one died of sinusoidal obstruction syndrome, one died of thrombotic microangiopathy and only one patient died of heart failure. This result indicates that diastolic dysfunction itself may negatively affect the patient's clinical course. Indeed, patients with an elevated E/e′ show poor prognosis in severe infection and liver cirrhosis. 6 Also in the present study, among nine patients who died of infection, seven patients were in the E/e′-high group. In HSCT, patients are at high risk of various complications, which are often related closely to each other, and these comorbidities will often militate against the post-transplant outcome either directly or indirectly. 7, 8 We also evaluated the clinical value of another two representative indicators of diastolic function: early peak flow velocity to atrial peak flow velocity (E/A) and deceleration time (DcT). However, they were not related to cardiac complications, NRM or OS in univariate (for cardiac complications) or multivariate (for OS and NRM) analyses. In patients with advanced diastolic dysfunction, DcT and E/A values tend to return to normal levels ('pseudonormalization'). 3, 9 Thus, these values seem to be unsuitable for proper evaluation of diastolic function.
Although the American Society of Echocardiography proposed to determine the presence of diastolic dysfunction using other indicators for patients with E/e′ values of 9-15, we could not perform detailed diastolic functional assessments for these patients, and this is one of limitations of our study. 3 In addition, we could not perform multivariate analysis for the cardiac event in the early phase of HSCT because of fewer events. However, the statistical significance of our results suggests that a high E/e′ value negatively affects the post-transplant course, and in contrast to EF, 10 the E/e′ value before HSCT may be a noninvasive, useful predictor of early cardiac complications, NRM and survival after HSCT.
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